STAT5A and neoplasm: Studies utilizing AML xenograft models in vivo confirmed the in vitro findings, wherein Zotiraciclib induced effective blockade of Stat3, Stat5 and CDK signaling leading to tumor regression and prolonged survival of mice carrying the tumors [214].